Regeneron Pharmaceuticals, Inc. $REGN Stock: Private Wealth Asset Management LLC Grows Stake

Private Wealth Asset Management LLC grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5,909.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,863 shares of the biopharmaceutical company’s stock after purchasing an additional 1,832 shares during the quarter. Private Wealth Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $1,413,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at $5,682,636,000. Legal & General Group Plc bought a new stake in Regeneron Pharmaceuticals during the second quarter valued at about $473,872,000. Bank of New York Mellon Corp purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $472,950,000. Aberdeen Group plc increased its position in Regeneron Pharmaceuticals by 560.7% in the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock worth $508,831,000 after buying an additional 569,476 shares in the last quarter. Finally, Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $323,249,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Recent Regeneron Pharmaceuticals Headlines

Here are a few of the latest headlines about REGN:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with anti-AChR-positive generalized myasthenia gravis. It is the first approved siRNA therapy for the condition and the only treatment given by subcutaneous injection just four times a year. Phase 3 results showed sustained disease control between doses, giving Regeneron a new neurology product and potential revenue source. Livsayis FDA approval announcement
  • Positive Sentiment: Regeneron plans to present new hematology data at the December ASH meeting, including potentially pivotal Ordspono results in marginal zone lymphoma. The data could provide further evidence of the company’s pipeline opportunity, though it is not yet a clinical or regulatory outcome. Regeneron ASH data announcement
  • Neutral Sentiment: Director Andrew Murphy sold 5,011 shares under a pre-arranged Rule 10b5-1 plan. He retained 46,779 shares afterward, making the transaction a limited signal about his view of the company. Insider transaction report

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. The trade was a 8.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Murphy sold 5,011 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $957.76, for a total transaction of $4,799,335.36. Following the completion of the sale, the insider owned 46,779 shares in the company, valued at approximately $44,803,055.04. The trade was a 9.68% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 32,039 shares of company stock valued at $29,825,285 in the last ninety days. Corporate insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on REGN shares. UBS Group raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. HSBC raised their target price on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Canaccord Genuity Group raised their target price on shares of Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a “buy” rating in a research note on Wednesday, October 28th. Finally, JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $904.41.

Get Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Down 0.3%

REGN stock opened at $920.69 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.35 and a quick ratio of 2.89. Regeneron Pharmaceuticals, Inc. has a 1-year low of $591.52 and a 1-year high of $991.73. The business has a 50 day simple moving average of $829.76 and a two-hundred day simple moving average of $752.07. The company has a market capitalization of $95.25 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.26 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm had revenue of $5.12 billion for the quarter, compared to analysts’ expectations of $4.58 billion. During the same quarter last year, the business posted $11.83 earnings per share. The company’s revenue for the quarter was up 36.3% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Read More

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.